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ABSTRACT 
ALK1, a TGF-β type I receptor serine/threonine kinase, is critical for proper vascular 
development. Heterozygous loss of ALK1 results in the vascular disorder, hereditary 
hemorrhagic telangiectasia type 2 (HHT2), which is characterized by the development of 
arteriovenous malformations (AVMs) and affects 1 in 5,000 people worldwide. HHT is thought 
to be caused by a haploinsufficiency and therefore delineating how ALK1 is regulated could 
provide avenues for targeted and effective clinical interventions. In the zebrafish model 
organism, alk1 is expressed in arterial endothelial cells of vessels leading away from the heart. 
We have learned that alk1 expression closely correlates with the presence of blood flow, but 
which component of blood flow is responsible for regulation is unknown. I propose that flow is 
required for activation of a positive feedback mechanism by which Bmp10 – a circulating ligand 
of Alk1 receptors that is produced by the heart and secreted into the bloodstream – through Alk1 
activation maintains arterial alk1 expression at the level of transcription. In this work, I define 
the spatiotemporal relationship between cessation and restoration of blood flow and alk1 
expression and show that flow-mediated alk1 expression is regulated at the transcriptional level. 
Finally, I provide evidence that intact Bmp10/Alk1 signaling is required to maintain alk1 mRNA 
expression. I hypothesize that this effect is driven by a gradient of Bmp10 ligand established by 
blood flow that triggers a positive feedback mechanism initiated by Bmp10/Alk1 signaling. The 
goal of my work is to understand the mechanism of ALK1 regulation in order to progress toward 
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the goal of targets and effective clinical management for HHT patients. HHT is a relatively 
common genetic disease that often goes underdiagnosed due to its variable presentation even 
among members of the same family, hence studying this complex disease is significant for 
practice of public health.  
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1.0  INTRODUCTION 
1.1 VERTEBRATE VASCULAR DEVELOPMENT 
1.1.1 Vasculogenesis 
Vasculogenesis is the process by which the first blood vessels arise from angioblasts, the 
precursors to vascular endothelial cells, during vertebrate embryonic development. The 
mechanism by which angioblasts differentiate is highly conserved among vertebrates and 
implicates members of the ETS and FOX families of transcription factors [1]. Angioblasts 
migrate in large clusters into cord-like structures, forming the major trunk vessels and primitive 
cranial and yolk sac plexuses, and then hollow out to carry blood flow, a process called 
lumenization [2].  
1.1.2 Angiogenesis 
Angiogenesis is the process by which nascent vessels established by vasculogenesis become 
remodeled and expanded. For example, plexuses, which are honeycomb-like structures of 
similarly sized vessels, remodel into a hierarchical network of arteries, capillaries, and veins [3]. 
This remodeling of the vasculature occurs via segment pruning, vessel splitting 
(intussusception), and vessel fusion [3]. The activation phase of sprouting angiogenesis involves 
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extension of new vessels from existing vessels and requires endothelial cell proliferation and 
migration [3]. Eventually, endothelial cells cease to migrate and proliferate, signaling the 
resolution phase of angiogenesis. During this phase, new vessels are stabilized by deposition of 
extracellular matrix while vascular smooth muscle cells and other support cells called pericytes 
are recruited to these sites, a process that is enabled by angiopoietin, PDGFB and TGF-β 
signaling [4, 5].  
1.2 HEREDITARY HEMORRHAGIC TELANGIECTASIA 
1.2.1 Clinical disease in humans 
Hereditary hemorrhagic telangiectasia (HHT) is a genetic syndrome that affects vascular 
development. It is categorized by the development of multiple arteriovenous malformations 
(AVMs), which are direct connections between arteries and veins in lieu of a capillary bed 
(Figure 1A). A loss of capillary structure results in compromised gas and nutrient exchange as 
well as susceptibility to rupture as higher than typical hemodynamic forces reach the veins [6]. 
AVMs in small vessels are referred to as telangiectases, which may be present in the skin, nasal 
mucosa, and gastrointestinal tract. A common symptom experienced by HHT patients is frequent 
nosebleeds, or epistaxis, due to rupture of nasal telangiectases; this can cause decreased quality 
of life and, if severe enough, life-threatening anemia requiring blood transfusions [6]. Large-
vessel AVMs can form in virtually any area of the body but are commonly found in the lung, 
liver, and brain in HHT patients, putting them at risk for stroke, heart failure, brain abscess, and 
death [7].  
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1.2.2 Molecular genetics of HHT 
1.2.2.1  TGF-β superfamily signaling 
The exact disease mechanism of HHT is not well understood but stems from decreased 
transforming growth factor-β (TGF-β) superfamily signaling in vascular endothelial cells. In 
TGF-β family signaling, ligands dimerize and bind to a complex of type I and type II receptor 
serine/threonine kinases (Figure 1B). Ligand binding is aided by non-signaling type III receptors. 
Complex formation allows the phosphorylation of type I receptors by type II receptors. Type I 
receptors then go on to phosphorylate corresponding intracellular receptor-specific (R)-SMADs 
which pair with SMAD4 proteins to cross the nuclear membrane and regulate gene transcription.  
The family of TGF-β ligands is large and can be divided into multiple sub-families. Ligands in 
the TGF-β and activin subfamilies bind to receptor complexes that phosphorylate SMAD2 and 
SMAD3.  Bone morphogenetic protein (BMP) ligands bind to different receptor complexes that 
phosphorylate SMAD1, SMAD5 and SMAD9 [8]. 
1.2.2.2 Known genes implicated in HHT 
HHT is caused by genetic defects in at least three genes important for endothelial TGF-β family 
signaling. Heterozygous mutations in endoglin (ENG), which encodes a type III receptor, cause 
HHT1 [9] while mutations in ACVRL1, which encodes the type I receptor activin receptor-like 
kinase 1 (ALK1), result in HHT2 [10] (Figure 1B). Mutations in these genes account for up to 
96% of cases of HHT [11]. Another 2% of cases are caused by heterozygous mutations in 
MADH4 [11] which encodes the common protein, SMAD4, required for most transcriptional 
responses involving the TGF-β protein superfamily. Mutations in MADH4 cause combined HHT 
and juvenile polyposis syndrome (HHT-JPS) [12].   
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Figure 1. Arteriovenous malformations are a result of improper TGF- β signaling.   
(A) Components of an AVM compared to a normal capillary bed. Arteries are red, veins are blue. Yellow circle 
signify oxygen molecules. (B) The TGF-β signaling pathway in arterial endothelial cells and its association with 
hereditary hemorrhagic telangiectasia. 
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1.2.3 Disease management 
International guidelines for care of patients with HHT have been established [13]. Interventions 
for HHT patients suffering from epistaxis include laser ablation, septal dermoplasty (in which 
thicker skin is grafted onto the inside of the nose), and surgical nasal closure.  Current 
pharmaceutical options non-specifically inhibit angiogenesis (i.e., bevacizumab) or enhance 
blood clotting (i.e. tranexamic acid) which produce unwanted side effects and only address 
disease symptoms and not underlying pathology [14]. Anemia and gastrointestinal bleeding are 
addressed with iron replacement therapy, blood transfusions, and avoidance of anti-coagulant 
and anti-inflammatory agents [13]. Treatment of AVMs is limited by their location. AVMs found 
in the lung can be reasonably managed via surgical embolization, in which a tiny metal coil or a 
small balloon is inserted via a catheter to block off the artery upstream of the AVM [15]. Brain 
AVMs are less likely to lead to complications, and surgical options including resection, ablation, 
and embolization are reserved for high-risk AVMs. Liver AVMs, if large or many in number, put 
a patient at risk for high-output cardiac failure due to decreased vascular resistance, necessitating 
liver transplant [7]. Overall, surgical interventions carry risks and are not completely effective in 
managing HHT. Surveillance for these patients includes annual evaluations for anemia, pulse 
oximetry testing to monitor for pulmonary AVMs (within the first decade of life), contrast 
echocardiogram every 5 years, baseline brain MRI in childhood, and periodic screening for GI 
polyps unless JP-HHT has been ruled out through molecular genetic testing [13]. 
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1.2.4 Genetic Counseling for HHT 
HHT is an autosomal dominant condition affecting as many as 1 in 5,000 individuals worldwide 
[14] and demonstrates age-related penetrance and highly variable expressivity even among 
family members [16, 17]. Individuals with HHT typically inherit their genetic mutation from a 
parent, but there is an estimated 3% rate of de novo mutations [18], and there are instances of 
somatic mosaicism [19]. Each child of a patient with HHT has a 50% chance of inheriting the 
mutation. The risk to siblings depends on the genetic status of the parents. Testing of at-risk 
asymptomatic individuals, including children and adolescents, may be warranted given the 
potential of early age of onset of symptoms but should include pre-test counseling to discuss the 
potential impact of positive or negative results. Genetic testing is not useful in providing 
information regarding age of onset, possible symptoms, or disease severity, and it should be 
offered to individuals whom meet a “suspected” or “definite” diagnosis of HHT using the 
Curaçao criteria [20]: 
 “1. Epistaxis: spontaneous, recurrent nosebleeds 
  2. Multiple (muco-)cutaneous telangiectases 
  3. Visceral lesions such as: 
– gastrointestinal telangiectasia (with or without bleeding) 
– pulmonary AVM (arteriovenous malformation) 
– hepatic AVM 
– cerebral AVM 
4. Family history with an HHT-affected first-degree relative” 
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1.3 ACVRL1/ALK1 
Because phenotype is thought to result from a haploinsufficiency [21], upregulation of ENG or 
ALK1 expression is a potential avenue for the development of therapeutics that specifically target 
AVM development in HHT patients.  
1.3.1 Ligands of ALK1 receptors 
The ligands TGFβ1, TGFβ3, BMP9, and BMP10 can induce ALK1 phosphorylation of 
downstream SMAD1, 5 and 9 in cultured endothelial cells [22-24]. However, BMP9 and BMP10 
are the only ligands that bind to ALK1 in vitro with high affinity [24–26]. BMP9 is produced 
mainly by hepatocytes and to a smaller degree by the lungs and brain [27, 28] while BMP10 is 
synthesized by the heart [29, 30]. Both ligands are generated as proproteins that are cleaved 
intracellularly into an N-terminal prodomain and a C-terminal growth factor domain [30]. These 
fragments remain noncovalently bound and are secreted as propeptide/growth factor complexes, 
or pro-complexes. Both proBMP9 and proBMP10 can activate ALK1 on endothelial cells and 
both circulate at physiological levels sufficient for ALK1 activation in mice and humans [24, 30, 
31]. Mutations in BMP9 have been associated with a vascular phenotype similar to but distinct 
from HHT [11], whereas there is not yet a genetic association between BMP10 and vascular 
defects.  
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1.3.2 Functional studies in Alk1 in mice 
Numerous mouse models have been developed to better understand how Alk1 functions to 
prevent AVMs. In an Alk1LacZ knockin model that expresses LacZ as a proxy for Alk1, β-
galactosidase activity is predominantly in the endothelial cells of developing arteries. Alk1 is 
reduced in adult arteries but increased in newly developing arteries secondary to wound healing 
and tumorigenesis [32]. These data suggest that Alk1 function is required during angiogenesis but 
may be less important after vessels have stabilized. 
As expected, Alk1 is critical for proper arteriovenous connections in mice. Lethal AVMs 
form in embryonic mice with global or endothelial cell-specific loss of Alk1. These mice exhibit 
enlarged vessels with defective vascular smooth muscle coverage and upregulation of mitogens 
specific to endothelial cells [33, 34]. Global or endothelial-specific loss of Alk1 expression in 
adult mice also results in the development of AVMs in vessels undergoing angiogenesis [33-35].  
Knockout of Bmp9 in mice does not produce embryonic AVMs but does result in a subtle 
postnatal vascular phenotype (patent ductus arteriosus) and minor defects in lymphatic structure 
and function [36, 37]. In contrast, Bmp10 knockout produces cardiac and vascular defects in the 
early embryo, including AVMs similar to Alk1 loss [33, 38–40]. These findings suggest that 
BMP10 is the key circulating ligand for ALK1 in endothelial cells, at least during embryonic 
development.  
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1.3.3 Functional studies of alk1 in zebrafish 
1.3.3.1 Zebrafish as a model organism for studying vasculature 
Zebrafish (Danio rerio) are an ideal model organism because they are inexpensive to maintain in 
large numbers relative to mice. Zebrafish have a short generation time and reach sexual maturity 
within three months. Zebrafish clutches may contain hundreds of offspring that can be collected 
easily, and embryonic development is complete by 5 days post fertilization. Zebrafish are fitting 
model for studying HHT because embryos are optically clear, which allows for the study of heart 
rate, blood flow, and vascular development noninvasively and in real time.  
1.3.3.2 Blood flow and vasculature in zebrafish 
Blood flow begins in zebrafish around 26 hours post-fertilization (hpf), and the vascular network 
in zebrafish embryos at 36 hpf (Figure 2A) is as follows: blood leaves the heart through the first 
aortic arch (AA1) and flows cranially into the internal carotid artery (ICA), then caudal divisions 
of the internal carotid artery (CaDI), and the basal communicating artery (BCA). From the BCA, 
blood then flows through posterior communicating segments (PCS) and into the basilar artery 
(BA) and drains to neighboring veins (primoridal midbrain channel, PMBC; and primoridal 
hindbrain channel, PHBC) via transient vessel segments. Blood also flows caudally into the 
lateral dorsal aortae (LDA) and dorsal aorta (DA) before draining to the posterior cardinal vein.  
In these early embryos, alk1 is exclusively expressed in arterial endothelial cells in vessels most 
proximal to the heart, including AA1 and the cranially-directed ICA, CADI, and BCA, as well as 
the caudally-directed LDA and DA (Figure 2A). Expression of alk1 in these vessels initiates with 
the onset of blood flow [41] and is maintained at least through 5 days post-fertilization (dpf) (B.  
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Figure 2. Zebrafish embryos require Alk1 for proper development of the cranial vessels.  
(A) Cranial arties (red) that are known to express alk1 starting at 26 hpf.  Blue arrows show the direction of blood 
flow as it leaves the heart and travels towards the head or tail. Dashed lines indicate arteries positioned closer to the 
reader. Scale bar = 100 µm. AA1, first aortic arch; ICA, internal carotid artery; CaDI, caudal divisions of the 
internal carotid artery; BCA, basal communicating artery; LDA, lateral dorsal artery; DA, dorsal aorta; BA, basilar 
artery; PCS, posterior communicating segments; MTA, metencephalic artery; CTA, central artery. (B) Dorsal view 
of 52 hpf Tg(flik1:gfp)la116;Tg(gata1:dsred)sd2 embryos showing loss of Alk1 results in enlargement of vessels and 
arteriovenous shunts (white arrowhead). Scale bar = 50 µm. 
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Roman, unpublished). In summary, the arterial segments closest to the heart, but not downstream 
cranial  arteries or any veins, become alk1 positive at the onset of blood flow [41].  
1.4 AVM DEVELOPMENT 
AVMs develop in zebrafish alk1 mutants in a highly predictable time and location, making them 
an good model for studying the processes that result in AVM formation when Alk1 signaling is 
lost [42].  The development of AV shunts in alk1 mutants is a two-step process. In the first step, 
alk1-dependent cranial arteries enlarge in part due to increased endothelial cell number [42]; 
specifically, there is a 1.2 fold increase in endothelial cells in the BCA/PCS at 32 hpf and a 1.8-
fold increase by 48 hpf [41].  Careful analysis of cranial arterial endothelial cell number in wild 
type embryos, alk1 mutant embryos and embryos lacking blood flow between 26 and 48 hpf 
revealed that there was a similar increase in cell number between 32 and 40 hpf in the alk1 
mutants and embryos lacking blood flow, suggesting that loss of blood flow and loss of alk1 
have the same effect on arterial endothelial cell number [41].  This observation suggests that 
Alk1 mediates a blood flow response. In support of this theory, a subset of shear stress-
responsive genes is dysregulated in alk1 mutants.  Specifically, cxcr4a, a promigratory 
chemokine receptor is upregulated while endothelin-1, a vasoconstritive peptide is 
downregulated in both alk1 mutants and embryos lacking flow [41].  Additionally, endothelial  
phosphorylation of Smad1/5/9 is lacking in embryos without blood flow or Alk1 receptors [40]. 
Gene expression and Smad1/5/9 phosphorylation can be restored in the absence of blood flow if 
the ligand, Bmp10, is injected into the vasculature of embryos transgenically expressing alk1 in 
endothelial cells [40].  These results suggest that flow functions to deliver the heart-derived 
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ligand, Bmp10, in order to activate Alk1, regulate expression of a subset of shear stress-
responsive genes, and restrict the number of endothelial cells in the cranial arterial endothelium.   
The second step in AVM development in alk1 mutants is failed regression of at least one 
of the transient BCA/PMBC or BA/PHBC connections downstream of the enlarged BCA. 
However, AVMs do not arise in alk1 mutants in the absence of blood flow. Shear stress is the 
frictional force exerted by blood flow parallel to the direction of flow and is transduced by 
endothelial cells into biochemical signals [43]. The force of shear stress is directly proportional 
to the rate of flow and blood viscosity. Vessels adapt to accommodate increased shear stress by 
remodeling to bring this force back down to a particular set point. Therefore, the lack of AVMs 
in alk1 mutants in the absence of flow suggests that AVMs are a compensatory response to 
altered shear stress. That is, increased vessel caliber in alk1-dependent arteries increases flow 
rate and shear stress in downstream arteries, resulting in an increased hemodynamic load. In 
response to this force, normally transient connections are maintained and even enlarge in an 
attempt to normalize shear stress, thus creating an AVM [41]. This hypothesis is supported by 
computational fluid dynamic modeling (P. Menon and B. Roman, unpublished).  
1.5 bmp10 AND bmp10-like IN ZEBRAFISH 
Analysis of the zebrafish genome revealed two bmp10 paralogs – bmp10 and bmp10-like – which 
likely arose during a whole genome duplication event [44]. Both bmp10 and bmp10-like are 
expressed exclusively in the heart. bmp10 is expressed in endocardial cells of the ventricle by 28 
hpf and expands to both chambers of the zebrafish heart by 36 hpf. bmp10-like is first detectable 
at 36 hpf and is restricted to distal ventricle and outflow tract myocardium [40]. Knockdown of 
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bmp10 is sufficient to produce AVMs similar to alk1 mutants, but phenotype is not as penetrant 
or expressive as in alk1 mutants. Knockdown of bmp10-like alone does not yield any effect on 
vasculature.  However, knockdown of both bmp10 and bmp10-like yield AVMs as robustly as 
alk1 mutants [40]. Combinations of bmp9, bmp10, and/or bmp10-like knockdowns do not yield 
any additional phenotypic effect [40]. These data suggest that bmp10-like acts redundantly with 
bmp10 and that Bmp10 – rather than Bmp9 – is the critical Alk1 ligand required for proper 
embryonic vascular development in zebrafish, as in mice. 
1.6 REGULATION OF ALK1 EXPRESSION 
Because HHT is thought to be caused by ALK1 or ENG haploinsufficiency, one approach to 
development of therapeutics is to enhance expression of the wild type copy of the disease gene. 
There is limited information regarding the regulatory elements that govern ALK1 gene 
expression. 
1.6.1 Regulatory elements 
ChIP assays performed on arterial endothelial cells show that the 5’ proximal promoter region of 
ALK1 lacks TATA/CAAT boxes but has GC-rich Sp1 consensus sites [45]. Loss of these Sp1 
sites results in lack of ALK1 transcription, and increasing doses of Sp1 result in increased 
transcription [45]. In response to angiogenic stimuli, such as vascular injury, ALK1 expression 
rapidly increases in endothelial cells [46]. This response is associated with nuclear translocation 
of Kruppel-like factor 6 (KLF6). Furthermore, Klf6 knockout mice display a down-regulation of 
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Alk1 mRNA in their vasculature, and Klf6+/- mice have lower transcriptional levels of Alk1 than 
their wild type siblings [46]. KLF6 interacts with the ALK1 promoter in endothelial cells during 
wound healing events – facilitated by Sp1. ALK1 expression is also indirectly increased in 
response to soluble factors released by cellular damage, such as interleukin 6 [46].  
An investigation into cis-acting elements necessary for artery specific Alk1 expression in 
mice revealed a 9.2 kb genomic fragment, including a 2.7 kb promoter region through intron 2, is 
sufficient to drive expression [47]. It is suggested that mouse intron 2 (corresponding to human 
and zebrafish intron 1) may contain enhancer elements as a shortened 4.8 kb regulatory element 
containing the Alk1 promoter and highly conserved regions within intron 2 showed specific 
expression in angiogenic arteries that was comparable to endogenous Alk1 [48]. However, how 
this intronic fragment directs arterial expression is unknown. 
1.6.2 Regulation by blood flow 
Several lines of evidence suggest that ALK1 expression is regulated by blood flow and/or shear 
stress. Alk1 is upregulated in manipulated mouse arteries that are predicted to experience a 
relatively high magnitude of shear stress [49]. Furthermore, zebrafish embryos with no heartbeat 
or blood flow due to genetic or pharmacological manipulations have undetectable alk1 
expression but normal vessel morphology and normal expression of pan-endothelial markers 
such as vascular endothelial cadherin (cdh5) [41]. It is not yet known, however, if the sensitivity 
of alk1 expression to blood flow is due to mechanical force acting upon endothelial cells or due 
to circulating endocrine factors.  
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1.7 HYPOTHESIS AND AIMS OF DISSERTATION 
Understanding the mechanism by which ALK1 expression is regulated will lend insight into 
development of drugs to overcome both ALK1 and ENG haploinsufficiency and prevent and/or 
rescue AVMs in HHT patients. Based on mouse and zebrafish models, it is apparent that some 
component of blood flow—either biochemical or mechanical—is required for ALK1 expression 
in arterial endothelial cells. BMP10 is a good candidate for this flow-based factor, as it is a 
critical ligand of ALK1 receptors and it is a circulating protein derived from the heart. 
In this work I used zebrafish to test the hypothesis that blood flow is required for 
activation of a positive feedback mechanism by which Bmp10/Alk1 signaling maintains arterial 
alk1 expression at the level of transcription.  I pursued my hypothesis by first defining the 
spatiotemporal relationship between blood flow and alk1 expression. It was previously 
demonstrated that stopping heartbeat for 8 hours caused loss of alk1 expression [41]. In this 
work, I examined the spatiotemporal pattern of this effect and determined whether restoration of 
blood flow could restore alk1 expression. I then go on to determine whether flow-mediated 
regulation of alk1 occurs at the level of transcription. To test this hypothesis, we generated a 
zebrafish transgenic line that expresses egfp under the control of enhancer elements located in 
alk1 intron 1. Zebrafish alk1 intron 1 corresponds to mouse Alk1 intron 2, which directs gene 
expression to arterial endothelial cells [32]. I manipulated blood flow in these embryos to 
determine whether egfp behaves similarly to alk1, suggestive of transcriptional control. Finally, I 
tested the hypothesis that intact Bmp10/Alk1 signaling is required to maintain alk1 mRNA 
expression.  
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2.0  MATERIALS AND METHODS 
2.1 ZEBRAFISH LINES AND MAINTENANCE 
Adult zebrafish (Danio rerio) were maintained according to standard protocols and embryos 
were raised and staged using standard methods [50].  
Transgenic line Tg(fli1a:negfp)y7 was made by expressing nuclear-localized EGFP under 
the control of a 15 kb fragment of the zebraﬁsh ﬂi1a promoter [42]. This fli1a promoter fragment 
directs transgene expression to migrating angioblasts, endothelial cells, and early blood cells.  
The ptol2-alk1e5:egfp DNA construct contains a 1910 bp fragment of the first intron of 
the zebrafish alk1 gene upstream of a basal promoter driving egfp expression and was generated 
using Gateway cloning (Invitrogen, Carlsbad, CA, USA). This construct was injected into one-
cell embryos and F0 adults were screened for transgene transmission. We identified one founder 
that generated F1 offspring with EGFP expression in the same arteries of the head and tail that 
express endogenous alk1. We designated this line Tg(alk1e5:egfp)pt517. 
alk1y6 embryos were isolated from an ethylnitrosourea (ENU) mutagenesis screen on AB  
background.  The alk1y6 allele contains a missense mutation (p.L249F) in alk1 that is known to 
be a null allele with no resulting kinase activity [42].  Embryos that are heterozygous for the 
alk1y6 allele do not show any phenotype, while homozygous alk1y6 mutants develop embryonic 
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lethal AV shunts [42]. alk1y6;Tg(alk1e5:egfp)pt517 lines were established by crossing alk1y6/+ with 
hemizygous Tg(alk1e5:egfp)pt517 
bmp10pt527 mutants were generated via targeted TALEN-mediated mutagenesis [51] . In 
this line, an 8 bp deletion results in a frameshift that truncates Bmp10 prior to the growth factor 
domain at amino acid 48.  bmp10pt527;Tg(alk1e5:egfp)pt517 fish were made by crossing 
bmp10pt527/+ to hemizygous Tg(alk1e5:egfp)pt517. 
2.2 MORPHOLINOS 
Translation-blocking morpholino-modified antisense oligonucleotides (morpholinos; GeneTools, 
Philomath, OR, USA) were as follows: 
bmp10-like, 5’-GCAGCAGAGAATCAGCCATGACTGC-3’ 
Control, 5’-CCTCTTACCTCAGTTACAATTTATA-3’.  
2 ng of control and bmp10-like morpholinos were injected into 1 to 8-cell embryos from a 
bmp10pt527/+:Tg(alk1e5:egfp)pt517/+ incross and a subset were assessed for AVMs between 2-3 dpf 
and genotyped for bmp10pt527. Injecting 2 ng of bmp10-like morpholino into bmp10pt527/pt527  
generated a vascular phenotype identical to that seen in alk1-/- with 100% penetrance. Remaining 
embryos were fixed for in situ hybridization at 36 hpf. Only 50% of fixed embryos carried the 
alk1e5:egfp transgene. To eliminate experimental bias, embryos were not sorted for EGFP before 
fixation but were instead genotyped for the alk1e5:egfp transgene post-processing. 
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2.3 DRUG EXPOSURE AND EMBRYO COLLECTION 
To maintain optical clarity of the embryos, 0.003% phenylthiourea (PTU) was added to the 
embryo medium (Sigma, St. Louis, MO, USA) at 24 hpf. To stop heartbeat, dechorionated 
embryos were incubated 100 embryos per 100 mm dish in 800 µg/ml tricaine in 30% 
Danieau/0.003% PTU at 32 hours post-fertilization. Embryos were collected at designated time 
points and immediately placed in 4% paraformaldehyde and fixed at 4°C for 48-72 hours. After 
fixing, embryos were washed 5 times in 100% methanol and then stored at -20°C in 100% 
methanol.  
2.4 WHOLE MOUNT IN SITU HYBRIDIZATION 
Whole-mount in situ hybridization was performed as previously described [42]. Riboprobes were 
generated using a digoxigenin RNA labeling Kit (Roche, Indianapolis, IN, USA) (Table 1).  For 
alk1, cDNA amplified using forward primer 5’-GGCCCTGGGTCTCGTCTT-3’ and reverse 
primer 5’-ACCCCATCTTACCCTCACTTTAC-3’ was cloned into pCRII-TOPO vector 
(Invitrogen).  Complete egfp sequence was cloned into pCRII-TOPO vector. A 5’ RACE cdh5 
product was cloned into a pCRII-TOPO vector.  Pre-adsorbed sheep anti-dig-AP antibody was 
used at 1:5000 dilution. 
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Table 1. Plasmids and enzymes used to generate riboprobes. 
Ribroprobe Plasmid name Number  Restriction enzyme Polymerase 
alk1 alk1 pr3 w1-1 12 Spe1 T7 
Egfp EGFP 329 Not1 Sp6 
vecad/cdh5 Vecad 112 Not1 Sp6 
2.5 IMAGING AND PHENOTYPIC SCORING 
 Bright-field images were captured using an MVX-10 MacroView macro zoom microscope 
equipped with an MV PLAPO 1×/0.25 NA objective, 2× magnification changer, and DP71 
camera with DP controller software version 3.1 (Olympus America, Center Valley, PA, USA).  
Embryos were imaged and scored for gene expression in a blinded fashion, then digested for 
genotyping. Gene expression was scored as “positive” or “negative” based on whether staining 
(alk1, gfp, cdh5) was present in a particular vessel segment; namely, the first aortic arch (AA1), 
internal carotid artery (ICA), caudal division of the internal carotid artery (CaDI), basal 
communicating artery (BCA), and lateral dorsal aorta (LDA).  Images were compiled with 
Adobe Photoshop CS2 version 9.0.2 (Adobe Systems, San Jose, CA, USA).  
2.6 GENOTYPING 
DNA was isolated from zebrafish fin clips and individual embryos for genotyping assays in 
DNA isolation buffer (10mM Tris HCl pH8.0, 50 mM KCl, 0.3% Tween-20, 0.3% Nonidet P-40 
Substitute, 0.5 mg/mL Proteinase K) incubated at 50°C for 12-15 hours then at 98°C for 10 
minutes. Assays consisted of PCR using primers designed for the specific allele with or without 
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restriction enzyme digestion following amplification (Table 2). PCRs were run for 32 cycles and 
amplification products were visualized by 3% Metaphor agarose gel electrophoresis.  
 
Table 2. List of genotyping assays. 
Line Forward Primer (5’  3’) Reverse Primer (5’  3’) Enzyme Assay 
bmp10 
pt527 
CTCCCCGGAGAGGCACC
TCA 
AGGTGGCTCTACACGA
GTG DdeI 
dCAPS1; 
cuts M 
vbg y6 CACGGTCCAACTAAGGCATGAAAACACCTT 
ATGGACAGAGAAGTGT
AAGTAAGAAAT BsaJ1 
dCAPS; 
cuts WT 
tg(alk1e
5:gfp)pt
517 
ACACTATCTGATTTGAG
AAAC 
AAGTCGTGCTGCTTCAT
GTG No Digest 
1 band 
alk1e5 + 
(459 bp) 
egfp TGGTGCCCATCCTGGTCGAGCTGG 
AAGTCGTGCTGCTTCAT
GTG No Digest 
1 band 
(217 bp) 
1dCAPS: derived cleaved amplified polymorphic sequence [52] 
2.7 STATISTICS 
Statistical comparisons were made by Fisher’s Exact Test using online calculation tool [53] with 
significance set at p<0.05. The number of experimental replicates and n values are detailed in 
Table 3. 
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Table 3. Experimental replicates and n values (experimental repeats, n embryos total). 
variable alk1 egfp cdh5 
Flow Time course    
32 hpf control 3, 117 3, 86 3, 107 
40 hpf control 3, 50 3, 67 3. 80 
42 hpf control 3,103 3, 66 3, 81 
48 hpf control 3, 87 3, 66 3, 103 
32 hpf tricaine 3, 133 3, 68 3, 97 
40 hpf tricaine 3. 70 3, 55 3, 72 
42 hpf tricaine + washout 3, 106 3, 58 3, 99 
48 hpf tricaine+washout 3, 144 3, 57 3, 100 
Alk1 Loss of Function    
alk1+/+ 3, 82 2, 23 2, 14 
alk1 +/- 3, 130 2, 26 2, 31 
alk1-/- 3, 119 2, 14 2, 12 
Bmp10 Loss of Function    
bmp10pt527+/+  
control MO 
3, 19 3, 10 3, 15 
Bmp10pt527+/-  
control MO 
3, 24 3, 35 3, 18 
Bmp10pt527-/-  
control MO 
3, 7 3, 27 3, 3 
Bmp10pt527+/+ 
Bmp10-like MO 
3, 17 3, 24 3, 16 
Bmp10pt527+/- 
Bmp10-like MO  
3, 41 3, 24 3, 24 
Bmp10pt527-/- 
Bmp0-like MO 
3, 18 3, 7 3, 8 
Tg(fli1a:negfp)y7  
without flow 
   
36 hpf control 1, 30 1, 26 1, 31 
36 hpf tricaine 1, 27 1, 27 1, 35 
Tg(fli1a:negfp)y7  + Alk1 
loss of function 
   
alk1+/+ 1, 7 1, 29 1, 8 
alk1 +/- 1, 28 1, 74 1, 8 
alk1-/- 1, 8 1, 23 1, 4 
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3.0  RESULTS 
3.1 BLOOD FLOW ACUTELY REGULATES alk1 mRNA EXPRESSION  
It has previously been shown that alk1 is not expressed in the absence of blood flow following a 
tricaine treatment at 32-40 hpf as well as in tnnt2a morphant embryos with noncontractile hearts 
[41].  In order to define the spatiotemporal relationship between blood flow and alk1 expression 
over a timecourse, as well as to observe alk1 response after flow restarts, I stopped the heartbeat 
of zebrafish between 32 hpf and 40 hpf using a 5x dose of the anesthetic, tricaine. I started 
tricaine treatment at 32 hpf because blood flow is robust and alk1 expression in the arterial 
endothelium in the head (AA1, ICA, CaDI, BCA) and trunk/tail (LDA, DA) has been established 
by this time point. Furthermore, the embryo’s demands for oxygen at this time can be met by 
diffusion; therefore, embryos without blood flow are not hypoxic [54].  
I determined the presence of blood flow by visually examining the optically clear 
embryos for the movement of red blood cells through the head, trunk, and tail. Heartbeat was 
noticeably slowed within 30 minutes after tricaine treatment compared to untreated controls. By 
60 minutes, about two-thirds of tricaine-treated embryos had no heartbeat or blood flow. For the 
other one-third of embryos there was still a steady but dramatically slowed rate of twitching of 
the heart at this time, but there was no blood flow. I collected tricaine-treated and untreated 
sibling embryos at 34 hpf and 40 hpf for in situ hybridization for alk1 and cdh5 (Figure 3B).  
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After 8 hours of tricaine exposure (40 hpf), embryos were moved to fresh water. 
Heartbeat and blood flow resumed in washed out embryos within one hour post-washout (41 hpf) 
and blood flow looked identical to flow in control embryos by two hours post-washout (42 hpf). 
I then washed remaining embryos out of tricaine to allow heartbeat to restart and collected 
embryos at 42 and 48 hpf for in situ hybridization for these same genes. Gene expression was 
scored as positive or negative (+/-) in each arterial vessel segment, and data are presented as 
percent of embryos with expression in each segment. 
At 34 hpf, alk1 expression was detectable in untreated embryos in all expected arterial 
vessel segments. In contrast, alk1 expression was lost in some segments after 2 hrs tricaine 
exposure, with effects greater in distal versus proximal segments (% embryos with alk1 
expression, AA1, LDA > ICA > CaDI >BCA). At 40 hpf, alk1 expression was detectable in most 
vessel segments in untreated embryos but was absent from nearly all vessel segments after 8 hrs 
of tricaine treatment (Figure 3B), with an average of 5.26% of embryos retaining some 
expression in AA1 only (Figure 3D). The pan-endothelial marker, cdh5, was unaffected by 
tricaine treatment. 
At 42 hpf, alk1 expression was detected in all arterial vessel segments in all untreated 
embryos and in most arterial vessel segments in most tricaine-treated embryos, with more 
complete recovery in proximal (AA1, ICA, LDA) versus distal (CaDI, BCA) segments (Figure 
3C, E). alk1 expression was fully recovered by 8 hrs post-tricaine exposure (48 hpf). cdh5 
expression remained unchanged in tricaine-treated versus untreated controls at all times.  
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Figure 3. Cessation of blood flow results in loss of alk1 expression, with distal arteries more sensitive to flow 
loss than proximal arteries.  
(A)  Schematic of experimental design showing times of treatment, washout, and embryo collection. (B) Embryos 
were treated with 800 µg/ml tricaine in 30% Danieau/0.003% PTU at 32 hpf to stop blood flow, fixed at 2 hours and 
8 hours post treatment, and stained via whole mount in situ hybridization for alk1 or cdh5.  Lateral and frontal 
views, as indicated. (C) Embryos were removed from tricaine after 8 hours of exposure to restore blood flow, fixed 
at 2 hours and 8 hours post washout, and stained via whole mount in situ hybridization for alk1 or cdh5. Arrows 
denote basal communicating artery, black; caudal division of the internal carotid artery, yellow; internal carotid 
artery, blue; first aortic arch, grey; lateral dorsal aorta, white.  Scale bar = 100 µm. (D, E) Embryos were scored for 
the presence or absence of alk1 in arterial segments at 2- and 8-hrs post-tricaine treatment (D) and at 2- and 8-hrs 
post-washout (E); data are presented as percent of embryos with positive expression. n ≥ 50 for each time point over 
three independent experiments. Embryos scored for alk1 expression were analyzed by Fisher’s exact test with 
significance set at 0.05. (**** signifies p<0.0001, * <0.05) 
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Together, these data demonstrate that arterial endothelial alk1 mRNA expression is 
exquisitely sensitive to blood flow. alk1 expression is significantly diminished within 1-2 hrs of 
flow cessation, particularly in arterial segments distal to the heart, and nearly undetectable within 
8 hrs of flow cessation. Conversely, reinitiating heartbeat and blood flow allows alk1 re-
expression within 2 hrs, with more rapid effects in proximal versus distal arterial segments.  
3.2 FLOW REGULATION OF alk1 EXPRESSION OCCURS AT THE LEVEL OF 
mRNA TRANSCRIPTION 
To determine whether regulation of alk1 mRNA expression by blood flow occurs 
transcriptionally or post-transcriptionally, I treated Tg(alk1e5:egfp)pt517 embryos, in which egfp 
expression is driven by a basal promoter and zebrafish alk1 enhancer (intron 1), with tricaine 
between 32 and 40 hpf and collected embryos during tricaine exposure (34 hpf, 40 hpf) and after 
washout (42 hpf, 48 hpf). These embryos were siblings of embryos analyzed for alk1 and cdh5 
expression. In situ hybridization revealed that egfp mRNA exhibited the same temporal response 
to cessation and reinitiation of blood flow as alk1 mRNA (Figure 4A, B).  However, egfp mRNA 
was more refractory to flow loss than alk1 mRNA in AA1, and egfp recovery after flow initiation 
was slower and less robust than alk1 (Figure 4C, D). To ensure that effects of flow manipulation 
on egfp mRNA expression were not due to egfp transcript instability in the absence of flow, I 
treated Tg(fli1a:negfp)y7  embryos with tricaine, 32-40 hpf. At 40 hpf, I found nearly complete 
loss of alk1 expression (Figure 5B), as expected, but no effect of flow loss on fli1a-driven 
endothelial egfp expression (Figure 5A). Taken together, these results suggest that alk1 
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Figure 4. Blood flow regulates alk1 expression at the level of transcription. 
 (A) Tg(alk1e5:egfp)pt517 embryos were treated with tricaine at 32 hpf to stop blood flow and fixed in 4% 
paraformaldehyde at 2 hours and 8 hours post treatment. (B) Embryos were removed from tricaine treatment after 8 
hours of exposure and blood flow was restored. Embryos were fixed at 2 hours and 8 hours post washout. Whole 
mount in situ hybridization for egfp was performed and embryos were scored for the presence of expression in 
arteries in lateral and frontal views. n ≥ 55 for each timepoint over three independent experiments. Arrows denote 
basal communicating artery, black; caudal division of the internal carotid artery, yellow; internal carotid artery, blue; 
first aortic arch, gray; lateral dorsal aorta, white. Scale bar = 100 µm.   (C-D) Embryos scored for egfp expression 
were analyzed by Fisher’s exact test with significance set at 0.05. (**** signifies p-value <0.0001, *** 0.0001 to 
0.001, * 0.01 to 0.05). 
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regulation by blood flow occurs at the level of transcription and is mediated by cis elements in 
alk1 intron 1.   
 
 
 
Figure 5. Loss of blood flow has no effect on fli1a-driven egfp expression in endothelial cells. 
(A-C) Tg(fli1a:egfp)y7 embryos were treated with tricaine at 32 hpf and then to stop blood flow and fixed in 4% 
paraformaldehyde at 8 hours post treatment. Whole mount in situ hybridization for egfp (A), alk1 (B), or cdh5 (C) 
was performed and embryos were scored for the presence of expression in arteries in lateral, and frontal views. In 
control and treatment groups, n = 31 and 35 for egfp, 30 and 27 for alk1, and 27 and 26 for cdh5, respectively. 
Arrows denote basal communicating artery, black; caudal division of the internal carotid artery, yellow; internal 
carotid artery, blue; first aortic arch, grey; lateral dorsal aorta, white. Scale bar = 100 µm. 
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3.3 INTACT Bmp10/Alk1 ACTIVITY IS REQUIRED FOR alk1 EXPRESSION 
I reasoned that Alk1 activity may be required to maintain alk1 mRNA expression by a positive 
feedback mechanism given previous findings that demonstrated that alk1 mRNA expression is 
decreased in alk1y6 mutants [41].  This missense transcript generates a kinase-dead, full length 
Alk1 mutant protein [42] and therefore alk1 loss is unlikely due to inherent transcript instability. 
To test this hypothesis, I crossed alk1y6/+;Tg(alk1e5:egfp)pt517 zebrafish to alk1y6/+ to produce 
embryos that were either wild type, heterozygous, or homozygous mutant for the alk1y6 allele. In 
situ hybridization with subsequent genotyping for the alk1y6 allele showed that alk1 expression 
was significantly decreased in all arterial segments at 36 hpf in alk1y6 homozygous mutants 
compared to wild type or heterozygous siblings (Figure 6A, D), whereas cdh5 was unaffected 
(Figure 6C). There was no significant difference in alk1 expression between wild type and 
heterozygote siblings (Figure 6D), suggesting that a partial level of alk1 activity is not sufficient 
to disrupt the proposed positive feedback loop via a haploinsufficiency in the embryonic 
zebrafish model. This is expected given that alk1y6 homozygous mutants develop AVMs, but 
their heterozygous siblings do not. 
egfp expression behaved similarly to alk1, although expression was less sensitive to alk1 
genotype and did not decrease in number of embryos to a degree as significant as alk1. To ensure 
that the egfp mRNA transcript itself was not affected by Alk1 activity, I crossed 
alk1y6/+;Tg(fli1a:negfp)y7  zebrafish to alk1y6/+ to produce embryos that were either wild type, 
heterozygous, or homozygous mutant for the alk1y6 allele. I found loss of alk1 expression as 
described previously, as expected, but no effect of loss on fli1a-driven endothelial egfp 
expression (Figure 7). 
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Figure 6. Evidence suggests that Alk1 participates in a self-regulatory pathway to maintain expression. 
alk1y6/+;Tg(alk1e5:egfppt17) fish were outcrossed to alk1y6/+ non-trangenics and then sorted for the presence of the 
egfp transgene at 30 hpf.  Whole mount in situ hybridization was performed on resulting embryos for alk1 (A), egfp 
(B), and cdh5 (C) fixed at 36 hpf. Embryos were scored for the presence or absence of expression in vessels in 
lateral, dorsal, and frontal views and genotyping was subsequently performed on all embryos for y6 allele. For each 
y6 genotype, n ≥ 82 over three experiments for alk1, n ≥ 14 over two experiments for egfp, and n ≥ 12 over two 
experiments for cdh5. Arrows denote basal communicating artery, black; caudal division of the internal carotid 
artery, yellow; internal carotid artery, blue; first aortic arch, grey; lateral dorsal aorta, white. Scale bar = 100 µm. 
(D-E) Embryos scored for alk1 or egfp expression were analyzed by Fisher’s exact test with significance set at 0.05. 
(**** signifies p-value <0.0001, *** 0.0001 to 0.001, ** 0.001 to 0.01, * 0.01 to 0.05). 
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To investigate the concept of a circulating ligand, specifically Bmp10, as the component 
of blood flow required for alk1 expression, I crossed bmp10pt527 heterozygous fish to       
bmp10pt527:alk1e5:egfppt517 to yield offspring that were wild type, heterozygous, or homozygous 
mutant for the pt527 allele. Embryos were then either injected with bmp10-like morpholino or 
control morpholino at 1-8 cell stage. In situ hybridization of 36 hpf embryos was performed for 
alk1, cdh5, and egfp with subsequent genotyping for the pt527 allele. I observed that based on 
bmp10 genotype, alk1expression was decreased only in homozygous mutants, but not 
significantly except in the ICA (with a p-value of 0.047) which was just slightly significant 
(Figure 8A, D). It should be noted that the smaller number of embryos that were injected with 
control morpholino and were then determined to be homozygous mutant for the pt527 allele after 
scoring for expression (n = 7 for mutants with control morpholino versus n = 19 wild types and n 
= 24 heterozygotes) may have affected the potentially significant trend.  With the additional 
knockdown of bmp10-like, however, there was a significant decrease in homozygous mutants in 
the number of embryos with alk1 expression in all vessels (Figure 8A, D).  The combination of 
loss of bmp10-like and bmp10 heterozygotes was not significant in any vessels except for the 
BCA (with a p-value of 0.034). cdh5 expression was unaffected by pt527 genotype and/or 
bmp10-like morpholino (Figure 8C).  
Looking at bmp10 genotype alone, there was some noticeable decrease in egfp expression 
in bmp10 homozygous mutants compared to wild type and heterozygous siblings, but it was not 
significant or consistent across all of the vessels.  The combination of bmp10 and bmp10-like 
loss yielded some significant decrease in egfp expression in the AA1, ICA, and LDA, but it was 
not as strong or consistent as with alk1 (Figure 8B, E). 
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Figure 7. Loss of alk1 activity has no effect on fli1a-driven egfp expression in endothelial cells. 
(A-C) alk1y6/+;Tg(fli1a:negfp)y7  zebrafish were crossed to alk1y6/+ to produce embryos that were either wild type, 
heterozygous, or homozygous mutant for the alk1y6 allele. Whole mount in situ hybridization was performed on resulting 
embryos for egfp (A), and alk1 (B), and cdh5 (C) fixed at 36 hpf. Embryos were scored for the presence or absence of 
expression in vessels in lateral and frontal views and genotyping was subsequently performed on all embryos for y6 allele. For 
alk1 n = 7, 28, 8 for wild type, heterozygotes, and mutants, respectively. For egfp n = 29, 74, 23 for wild type, heterozygotes, 
and mutants, respectively. For cdh5, n = 8, 8, 4 for wild type, heterozygotes, and mutants, respectively. Arrows denote basal 
communicating artery, black; caudal division of the internal carotid artery, yellow; internal carotid artery, blue; first aortic 
arch, grey; lateral dorsal aorta, white. Scale bar = 100 µm. 
 
 
 
 
Overall, these data support bmp10/bmp10-like as being required for activation of Alk1 
activity and subsequently maintenance of alk1 expression. 
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Figure 8. alk1 expression requires Bmp10. 
(A-C) Tg(alk1e5:egfp); bmp10+/- were crossed to bmp10 +/- non-transgenics and then injected with control 
morpholino (MO) or bmp10-like morpholino (MO) and then fixed at 36 hpf. Whole mount in situ hybridization was 
performed for alk1 (A), egfp (B), and cdh5 (C) and embryos were scored for the presence of expression in arteries in 
lateral and frontal views. Embryos were then genotyped for the bmp10pt527 allele and for egfp. For wild type, 
heterozygous, and mutants, respectively, in control MO injected embryos: n = 19, 24, 7 (alk1); 10, 35, 27 (egfp); 15, 
18, 3 (cdh5) over three independent experiments. For wild type, heterozygous, and mutants, respectively, in bmp10-
like MO injected embryos, n = 17, 41, 18 (alk1); 24, 24, 7 (egfp); 16, 24, 8 (cdh5) over three independent 
experiments. (D-E) Embryos scored for alk1 (D) or egfp (E) expression were analyzed by Fisher’s exact test with 
significance set at 0.05. (**** signifies p-value <0.0001, ** 0.001 to 0.01, * 0.01 to 0.05). Scale bar = 100 µm. 
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4.0  DISCUSSION 
Decreased transforming growth factor β (TGF-β) signaling in vascular endothelial cells in 
humans, specifically a haploinsufficiency of ALK1 expression, results in hereditary hemorrhagic 
telangiectasia type 2 (HHT2). This disease is modeled by zebrafish embryos with a homozygous 
loss of alk1 in which arteriovenous shunts form in the cranial arteries at a predictable time in 
development. Studies have shown that alk1 is predominantly expressed in the endothelial cells of 
arteries undergoing angiogenesis, but its exact role has yet to be delineated. Because HHT2 is 
considered to be a result of a haploinsufficiency, studying the mechanisms that regulate ALK1 
expression is an area of research that could yield promising candidates for clinical treatment that 
is targeted towards HHT2 patients.  
4.1 SENSITIVITY OF alk1 TO FLOW 
In zebrafish, Alk1 receptors are only expressed in endothelial cells in vessels that are nearest to 
the heart. The dependence of alk1 on blood flow has been documented [41] and I have further 
characterized this relationship through time course experiments. alk1 expression is quickly lost 
subsequent to absence of blood flow. Loss of expression is first noticed in the vessels most distal 
from the heart (BCA, ICA, CaDI) followed by vessels more proximal to the heart (AA1 and 
LDA). Furthermore, when anesthetic is removed and blood flow returns to the embryo, alk1 
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expression returns to the most proximal vessels first before the more distal vessels. This 
gradient-like pattern from the heart outwards could support a number of hypotheses regarding 
which component of blood flow – whether a circulating element or mechanical forces including 
shear stress and/or circumferential strain – is specifically responsible for alk1 expression.  
4.2 ENDOCRINE LIGAND AS KEY FACTOR IN alk1 EXPRESSION 
Given that Alk1activity is required for alk1 expression [40], this suggests a feedback mechanism 
may be involved. If so, then loss of Bmp10 (bmp10-/-) should produce the same effect.   My study 
has examined the possibility of this endocrine factor as the underlying activator of alk1 
expression. As mentioned previously, Bmp10 is a strong candidate for this role. We have 
demonstrated that loss of Bmp10 results in vascular defects at the embryonic stage, similar to 
alk1mutants [40].  Furthermore, Bmp10 is derived from the heart and is detected in blood [40]. 
One could speculate that Bmp10 is the critical factor for alk1 expression due to the observed 
pattern of loss of alk1 expression in my time course experiments. I observed that with loss of 
blood flow alk1 expression initially persisted in vessels most proximal to the heart, which is also 
the source of Bmp10 ligand. My data support the concept of a gradient of Bmp10 ligand in 
arteries with highest concentrations of Bmp10 ligand closest to the heart and then diminishing as 
it follows along to more distal vessels. Loss of blood flow would therefore restrict the location of 
Bmp10 to the heart and only the most proximal arterial segments. The concept of a ligand 
gradient explains why I observed retained alk1 expression in vessels most proximal to the heart 
after blood flow cessation. When blood flow resumes, Bmp10 is carried from the heart and 
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circulates through arteries, which explains why I observed alk1 expression return first in the 
most proximal vessels and then later in the most distal vessels.    
I then hypothesized that if Bmp10 was the critical factor for promoting alk1 mRNA 
expression, then loss of Bmp10 signaling activity would result in loss of alk1 expression. I 
observed a decrease in alk1 in bmp10 homozygous mutants but the change was not statistically 
significant. One reason for this result may be that there were too few bmp10 mutants in our 
control group to prove significance. Another reason may be that bmp10 is not the only regulator 
of alk1expression. bmp10-like, a redundant bmp10 paralog ligand in the zebrafish genome that is 
also derived from the heart, may also serve to compensate for Bmp10. In this study I found that 
loss of bmp10-like alone does not significantly decrease alk1 expression (Figure 8A, statistics not 
shown) but the combination of bmp10 and bmp10-like loss does significantly decrease alk1 
expression. It may be that Bmp10  is the primary critical ligand with Bmp10-like is a secondary 
ligand in promoting Alk1 activity. We know that bmp10 is expressed starting at 28 hpf, and 
bmp10-like is expressed later starting at 36 hpf [40] I did my analysis on 36 hpf embryos, so it 
may be that at this stage in embryonic development, bmp10-like may not yet play a critical role 
in alk1 regulation in arterial endothelial cells.   
As mentioned earlier, I observed that loss of bmp10-like alone (in wild type embryos) 
does not have an effect on alk1 expression. I also observed that bmp10-like loss in bmp10 
heterozygotes did not show any significant difference in alk1 except in the BCA where there was 
a significant difference.  There are a several explanations for this finding. First, given that the 
BCA is the alk1-positive artery most distal from the heart, one could speculate that the 
concentration of Bmp10 ligand as it is carried away from the heart by flow is lower in the BCA 
than the more proximal arterial vessels. Perhaps the concentration of Bmp10 in the BCA, in 
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combination with Bmp10-like, is just enough to activate alk1 expression in the wild type state. If 
there is a loss of Bmp10-like, then half of the Bmp10 ligand in pt527 heterozygotes is no longer 
sufficient to maintain alk1 expression in this vessel.  Secondly, the loss of alk1expression in the 
BCA may be due to technical execution of the in situ hybridization. The BCA is deep within the 
head of the embryo and therefore getting the probe into this region to detect alk1 expression is 
more difficult. This could explain why mRNA expression for this vessel is more variable than 
other vessels closer to the embryo’s outer surface, but it does not explain the differences I 
observed between control and treated embryos.   
Overall, my data support the idea of a circulatory component distributed in a gradient 
pattern across proximal and distal blood vessels as playing a necessary role in alk1 activation.  
4.3 ROLE OF MECHANICAL FORCES  
Although my data support the notion that alk1 expression is self-regulated and/or regulated by a 
circulating factor, my study does not rule out the possibility that mechanical force may still play 
a role. The proposal that Alk1 is regulated by mechanical force has been suggested in the past.  In 
mouse models, Alk1 expression is upregulated in arteries presumably experiencing high shear 
stress [49]. Also, shear stress has been found to induce alk1 expression in endothelial progenitor 
cells [55].  Additionally, alk1 expression is more likely related to shear stress rather than 
circumferential strain due to the observation that alk1 loss affects the arterial lumen but not the 
thickness of the arterial wall [41]. On the other hand, gata1a mutants, which lack erythrocytes 
but still have plasma flow, have normal alk1 expression despite theoretically having lower blood 
viscosity and consequently lower shear stress on vessels. However, there is no observed change 
 37 
in expression of known shear-responsive genes (edn1, cxcr4a, and kil2a) in gata1a  mutants [41] 
which indicates that more research is needed to define the relationship between shear stress in 
the early embryo and its effects on downstream gene expression.  
Mechanical forces could potentially work in conjunction along with a circulating ligand 
in a complex to activate Alk1 activity and stabilize alk1 mRNA transcripts. Another theory may 
be that mechanical forces may be important in activating the circulating ligand i.e., releasing the 
growth factor domain of Bmp10 from its propeptide.  
4.4 REGULATION OF alk1 OCCURS AT THE LEVEL OF TRANSCRIPTION  
I also aimed to determine whether regulation of alk1 occurs at the level of transcriptional 
activity.  Stopping the blood flow of Tg(alk1e5:egfp)pt517 embryos, a reporter line in which EGFP 
expression is driven by an enhancer element from alk1 intron 1, showed that changes in egfp 
expression mimic changes in alk1 expression that result from a loss of blood flow. These data 
suggest that blood flow regulates alk1 at the level of transcription. Examination through whole 
mount in situ hybridization for egfp of Tg(alk1e5:egfppt517) embryos in conjunction with the y6 
mutations suggested that loss of alk1 expression is not due to decay of an unstable transcript but 
rather is due to a loss of alk1activity. Additionally, I showed that egfp transcriptional stability 
itself is not regulated by blood flow.  
 My experiments utilizing Tg(alk1e5:egfppt517) embryos were valuable in helping to 
delineate the level at which alk1 is regulated, but I have observed that egfp does not always 
mimic alk1 expression perfectly, most often following the same trend but being less significantly 
different than alk1. I note that there is more inherent variability in the expression of our 
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transgene when compared to endogenous alk1. Certain lines of fish, or even individual adult fish, 
may yield embryos that greatly differ in the robustness of their transgenic expression.  I did not 
pre-sort embryos for the presence of EGFP and instead genotyped them after in situ 
hybridization processing, and phenotypic scoring. Because I was not able to pre-sort transgenics, 
there is the potential that embryos within the same clutch expressed very different levels of 
EGFP. This variability may explain some of the differences I see between alk1 and egfp 
expression, but one also cannot rule out the possibility that additional regulatory elements for 
alk1 are missing in our transgenic line or egfp transcript has a longer half-life. Overall, my data 
suggest that Alk1 activation by Bmp10 is required for alk1 expression in a self-regulatory 
process.  
4.5 LIMITATIONS OF THE STUDY AND FUTURE DIRECTIONS 
In this study I used whole mount in situ hybridization for analysis of gene expression. While this 
method is powerful in its ability to illustrate patterns of gene expression specific to tissue 
location it is not a quantitative method. Real-time quantitative PCR (qRT-PCR) would be an 
invaluable method to confirm my observations and quantitate changes in gene expression.  
Additionally, it would be worth trying to identify particular cis elements within alk1 
intron 1 – the genomic fragment enhancer that drives egfp in our transgenic line 
Tg(alk1e5:egfp)pt517– that regulates alk1 by blood flow and Alk1 activity.  
Also, further examination into the role of Bmp10 and Bmp10-like as the key ligand for 
alk1 regulation is needed. Our lab has developed a bmp10-like mutant line of zebrafish to allow 
for the production of double bmp10 and bmp10-like mutants, which would be a more robust 
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method of studying the roles of these genes than using morpholinos. We plan to replicate my 
experiments with double mutants to further support Bmp10 as a regulator of alk1 expression. We 
also need to show that egfp stability is not changed by Bmp10/Bmp10-like loss. 
4.6 APPLICATIONS FOR CLINICAL MANAGEMENT OF HHT 
Delineating the mechanisms that regulate alk1 will allow for the exploration of possible avenues 
to upregulate alk1 as a means of preventing or treating AVMs. Because Bmp10/Alk1 signaling is 
required for alk1 expression, increasing the level of Bmp10 ligand could help to increase alk1 
expression in arterial endothelial cells. Bmp10 binds specifically to Alk1, which makes it an 
ideal therapeutic for targeted treatment. Earlier in the TGF-β pathway (See Figure 1), an increase 
in Bmp9 is thought to upregulate its receptor endoglin [56], so the proposal that Bmp10 may be a 
candidate for jumpstarting alk1 is a promising one.  
4.7 APPLICATIONS FOR GENETIC COUNSELING 
It is thought that HHT affects as many as 1 in 5,000 people. It would not be uncommon for a 
genetic counselor to interact with a patient with a personal or family history of the disease, but 
the condition often goes undiagnosed given its variable expressivity. Genetic counselors 
routinely ask about health information for common indications such as early-onset cancer, 
multiple miscarriages, or a pattern of intellectual disability when eliciting family history. A 
greater awareness of HHT would prove useful so that counselors may refer patients and families 
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that have a history of AVMs, telangiectasias, and/or epistaxis to the proper specialists. Use of the 
Curaçao criteria [20] is a quick way to determine which individuals should be referred for 
genetic testing of the genes implicated in HHT. One challenge that health providers may face is 
judging whether the patient/family is experiencing epistaxis and separating these cases from 
those with common nosebleeds. Online tools exist (Nosebleed Severity Score: 
https://www2.drexelmed.edu/HHT-ESS/) as an easily accessible reference for health care 
providers to address these discrepancies. Another challenge for genetic counselors and 
physicians when encountering a person/family with possible HHT is that clinics or physicians 
that are specifically knowledgeable about HHT (such as a Center for Excellence designated by 
CureHHT/The HHT Foundation, http://curehht.org/ ) may not be available in many cities, so 
there needs to be increased advocacy and funding to establish more clinics and increase 
physician awareness of the disease.  
4.8 PUBLIC HEALTH SIGNIFICANCE 
As discussed previously, HHT is a disease that affects a population that is large relative to other 
genetic conditions. The implementation of newborn screening (NBS) programs is heralded as the 
most successful public health intervention to come out of advances in genetic screening. Most of 
the diseases that are included in NBS have a prevalence that is the same or smaller than HHT, 
including phenylketonuria (PKU), the first screening test introduced on the population scale. 
Because it is as common as other genetic diseases for which we screen the public, one could 
argue that HHT deserves the attention of those who study public health. A good screening test 
that is both easy to administer and accurate in its detection, however, has not yet been developed. 
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There has been some investigation into identifications of plasma markers for HHT screening 
including various cytokines and pro-angiogenic factors (i.e., VEGF) which are elevated in the 
serum of HHT patients [57, 58]. Furthermore, the lack of available treatments and inability to 
predict disease course limits the utility of a screening measure, particularly in unaffected or 
mildly affected people. At this time, the best approach for discovering unidentified individuals 
with HHT likely lies in the hands of physicians and genetic counselors with knowledge of the 
disease and subsequent cascade screening of at-risk relatives.  
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